Cover Image
市場調查報告書

隱形眼鏡:醫療設備的開發平台評估

Contact Lenses - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 356608
出版日期 內容資訊 英文 204 Pages
訂單完成後即時交付
價格
Back to Top
隱形眼鏡:醫療設備的開發平台評估 Contact Lenses - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年08月01日 內容資訊: 英文 204 Pages
簡介

本報告提供全球隱形眼鏡市場上的主要開發中產品及其臨床實驗的進展調查,加上產品特性比較分析 (臨床實驗的各進展階段) ,並彙整主要企業簡介及代表性產品,近來的市場動靜 (新產品開發·認證,業績趨勢等)資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 隱形眼鏡概要

第3章 臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各市場區隔
  • 開發中產品:各地區
  • 開發中產品:各法規途徑
  • 開發中產品:各預估認證時期
  • 開發中產品:現在臨床實驗中的產品

第4章 臨床實驗中的開發中產品:各企業

  • 隱形眼鏡的企業:各臨床實驗階段的開發中產品
  • 隱形眼鏡:各臨床實驗階段的開發中產品

第5章 隱形眼鏡市場:企業·產品概要

  • Aeon Astron Corporation
    • 開發中產品及進行中的臨床實驗概要
  • Alcon Laboratories Inc
  • Apeliotus Ophthalmics
  • Auburn University
  • Axcelon Biopolymers Corp.
  • Bar-Ilan University
  • Bausch & Lomb Incorporated
  • Children's Hospital Boston
  • CooperVision, Inc.
  • EP Global Communications, Inc.
  • Euclid Systems Corporation
  • e-Vision Medical Devices, Inc.
  • Eyenovations
  • EyeYon Medical
  • Imperial College London
  • Johnson & Johnson Vision Care, Inc.
  • Massachusetts Eye and Ear Infirmary
  • Novartis AG
  • Ocular Dynamics, LLC
  • Ocutec Limited
  • Presbia Plc
  • Stanford University
  • SynergEyes Inc
  • The Hong Kong University of Science and Technology
  • The University of New South Wales
  • UltraVision CLPL
  • University of California, San Diego
  • University of Florida
  • University of Valencia
  • University of Washington
  • Valeant Pharmaceuticals International, Inc.
  • Visioneering Technologies, Inc.
  • VISTAKON Pharmaceuticals, LLC
  • Yolia Health

第6章 隱形眼鏡市場:目前的趨勢 (全54件)

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0384EPD

GlobalData's Medical Devices sector report, "Contact Lenses - Medical Devices Pipeline Assessment, 2017" provides an overview of Contact Lenses currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Contact Lenses pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Contact Lenses under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Contact Lenses and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Contact Lenses under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 11

2 Introduction 12

  • 2.1 Contact Lenses Overview 12

3 Products under Development 13

  • 3.1 Contact Lenses - Pipeline Products by Stage of Development 13
  • 3.2 Contact Lenses - Pipeline Products by Segment 14
  • 3.3 Contact Lenses - Pipeline Products by Territory 15
  • 3.4 Contact Lenses - Pipeline Products by Regulatory Path 16
  • 3.5 Contact Lenses - Pipeline Products by Estimated Approval Date 17
  • 3.6 Contact Lenses - Ongoing Clinical Trials 18

4 Contact Lenses - Pipeline Products under Development by Companies 19

  • 4.1 Contact Lenses Companies - Pipeline Products by Stage of Development 19
  • 4.2 Contact Lenses - Pipeline Products by Stage of Development 21

5 Contact Lenses Companies and Product Overview 23

  • 5.1 Aeon Astron Corporation Company Overview 23
    • 5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.2 Alcon Laboratories Inc Company Overview 25
    • 5.2.1 Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.3 Apeliotus Ophthalmics (Inactive) Company Overview 33
    • 5.3.1 Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.4 Auburn University Company Overview 35
    • 5.4.1 Auburn University Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.5 Axcelon Biopolymers Corp. Company Overview 36
    • 5.5.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.6 Bar-Ilan University Company Overview 37
    • 5.6.1 Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.7 Bausch & Lomb Inc Company Overview 38
    • 5.7.1 Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.8 Children's Hospital Boston Company Overview 42
    • 5.8.1 Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.9 CooperVision Inc Company Overview 43
    • 5.9.1 CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.10 EP Global Communications, Inc. Company Overview 48
    • 5.10.1 EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.11 Euclid Systems Corp Company Overview 49
    • 5.11.1 Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.12 e-Vision Medical Devices, Inc. Company Overview 50
    • 5.12.1 e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.13 Eyenovations Company Overview 51
    • 5.13.1 Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.14 EyeYon Medical Company Overview 52
    • 5.14.1 EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.15 Imperial College London Company Overview 53
    • 5.15.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.16 Johnson & Johnson Vision Care Inc Company Overview 54
    • 5.16.1 Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • 5.17 Massachusetts Eye and Ear Infirmary Company Overview 56
    • 5.17.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.18 Novartis AG Company Overview 57
    • 5.18.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.19 Ocular Dynamics, LLC Company Overview 58
    • 5.19.1 Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.20 Ocutec Ltd Company Overview 59
    • 5.20.1 Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.21 Presbia Plc Company Overview 60
    • 5.21.1 Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.22 RetMap Inc Company Overview 63
    • 5.22.1 RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview 63
  • 5.23 Stanford University Company Overview 64
    • 5.23.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 64
  • 5.24 SynergEyes Inc Company Overview 65
    • 5.24.1 SynergEyes Inc Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.25 The Hong Kong University of Science and Technology Company Overview 67
    • 5.25.1 The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.26 The University of New South Wales Company Overview 68
    • 5.26.1 The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.27 UltraVision CLPL Company Overview 69
    • 5.27.1 UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.28 University of California San Diego Company Overview 70
    • 5.28.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 70
  • 5.29 University of Florida Company Overview 72
    • 5.29.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.30 University of Valencia Company Overview 73
    • 5.30.1 University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.31 University of Washington Company Overview 75
    • 5.31.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview 75
  • 5.32 Valeant Pharmaceuticals International Inc Company Overview 77
    • 5.32.1 Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview 77
  • 5.33 Visioneering Technologies Inc Company Overview 90
    • 5.33.1 Visioneering Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 90
  • 5.34 VISTAKON Pharmaceuticals LLC Company Overview 94
    • 5.34.1 VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 94
  • 5.35 Yolia Health Company Overview 95
    • 5.35.1 Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 95

6 Contact Lenses- Recent Developments 96

  • 6.1 Jul 13, 2017: Visioneering Technologies Appoints Michelle Kirst as Territory Manager for New Jersey 96
  • 6.2 Jul 11, 2017: Visioneering Technologies Appoints Ron Makelke as Territory Manager for San Francisco 96
  • 6.3 Jul 06, 2017: Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX Contact Lenses 97
  • 6.4 Jul 06, 2017: Visioneering Technologies Appoints Carol Baez as Executive Territory Manager for Orange County/San Diego 97
  • 6.5 Jun 29, 2017: Visioneering Technologies Announces Connie Stewart as Territory Manager, Los Angeles 98
  • 6.6 Jun 27, 2017: Visioneering Technologies Names Mark Rapoport as New CFO 98
  • 6.7 Jun 22, 2017: Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International 99
  • 6.8 Jun 20, 2017: Visioneering Technologies Announces Dave Halverson as Territory Manager in Southern California 99
  • 6.9 Jun 19, 2017: Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications 100
  • 6.10 Jun 19, 2017: John Paulson Joins Valeant Board Of Directors 100
  • 6.11 Jun 13, 2017: KAMRA Corneal Inlay Helps College Administrator End Her Blurry Near Vision and Dependence on Reading Glasses 100
  • 6.12 Jun 10, 2017: Three-Year Study Indicates Pioneering Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% 101
  • 6.13 Jun 10, 2017: Three-year study says new contact lens therapy slows myopia progression in children by 59 percent 102
  • 6.14 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results 103
  • 6.15 Jun 01, 2017: The Cooper Companies Announces Second Quarter 2017 Results 104
  • 6.16 May 30, 2017: The German Court has Granted a Preliminary Injunction in Favour of VSY Biotechnology BV and Against Carl Zeiss Meditec 105
  • 6.17 May 23, 2017: Presbia Provides Update on US Staged Pivotal Clinical Trial For Flexivue Microlens 106
  • 6.18 May 22, 2017: Bausch + Lomb Introduces renu Advanced Formula Multi-Purpose Solution 106
  • 6.19 May 11, 2017: Hoya Reports Fourth Quarter and Full-Year Financial Results 107
  • 6.20 May 10, 2017: Carl Zeiss Meditec accelerates growth in the first six months of 2016/17 108
  • 6.21 May 09, 2017: Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range 109
  • 6.22 May 08, 2017: ZEISS Appoints New Fellow 109
  • 6.23 May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 110
  • 6.24 May 05, 2017: Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership 111
  • 6.25 May 03, 2017: Presbia to Participate in the 2017 ASCRS Symposium & Congress in Los Angeles, California 112
  • 6.26 May 02, 2017: KAMRA Corneal Inlay Utilizes Camera Technology to Sharpen and Clear Blurry Near Vision for Patients 112
  • 6.27 May 01, 2017: Visioneering Technologies Expands US Sales Force 113
  • 6.28 Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 113
  • 6.29 Apr 25, 2017: Essilor International: Revenue increases by 10% Q1 in line with planned 2017 growth trajectory 117
  • 6.30 Apr 04, 2017: Carl Zeiss Meditec Group achieves first half 2016/17 revenue of approximately EUR 588 million 120
  • 6.31 Mar 30, 2017: Bausch + Lomb ULTRA For Astigmatism Contact Lenses Introduced 120
  • 6.32 Mar 27, 2017: Visioneering Technologies Successfully Lists on ASX 121
  • 6.33 Mar 15, 2017: Bausch + Lomb Introduces Biotrue ONEday For Astigmatism Contact Lenses 122
  • 6.34 Mar 08, 2017: The KAMRA Corneal Inlay Brings Life Back into Focus for Patients with Presbyopia, Blurring Near Vision 122
  • 6.35 Mar 03, 2017: Visioneering Technologies Announces Launch of NaturalVue Sphere 1 Day Contact Lenses 123
  • 6.36 Mar 02, 2017: Johnson & Johnson Vision Expands Portfolio to Reach More Patients with ACUVUE OASYS 1-DAY Brand Contact Lenses for ASTIGMATISM 124
  • 6.37 Mar 02, 2017: The Cooper Companies Announces First Quarter Results 124
  • 6.38 Feb 28, 2017: Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance 125
  • 6.39 Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 129
  • 6.40 Feb 17, 2017: Essilor International Reports 2016 Financial Results 130
  • 6.41 Feb 10, 2017: Carl Zeiss Meditec Off to A Solid Start Into Business Year 2016/17 137
  • 6.42 Jan 31, 2017: Hoya Announces Third Quarter Financial Results 138
  • 6.43 Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 138
  • 6.44 Jan 26, 2017: Achievement of sales milestone for COPD products 139
  • 6.45 Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 140
  • 6.46 Jan 24, 2017: Visioneering Technologies Announces Pam Wyman as Director, Sales Operations & Inside Sales 147
  • 6.47 Jan 18, 2017: Bausch + Lomb Introduces Zen RC Scleral Contact Lenses 147
  • 6.48 Jan 17, 2017: Visioneering Technologies Announces Jeff Babbe as New Executive Territory Manager for Chicago, IL 148
  • 6.49 Jan 11, 2017: Paragon CRT Contact Lenses Approved by China Food & Drug Administration 148
  • 6.50 Jan 10, 2017: Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA For Presbyopia Contact Lenses 149
  • 6.51 Jan 10, 2017: Bausch + Lomb ULTRA for Presbyopia Contact Lenses Parameters Expanded 150
  • 6.52 Jan 10, 2017: Stephen Petranek Appointed to NexOptic Board 150
  • 6.53 Jan 04, 2017: Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors 151
  • 6.54 Jan 04, 2017: First Contact Lenses Specifically Designed for Digital Lifestyles Makes their CES Debut 152
  • 6.55 Dec 21, 2016: Visioneering Technologies Announces Brian Atkinson as Territory Manager for the Dallas/Ft. Worth Market 153
  • 6.56 Dec 13, 2016: Visioneering Technologies Announces Ken Gold as New Executive Territory Manager for the Baltimore-Washington, DC Area 153
  • 6.57 Dec 12, 2016: Bausch + Lomb Specialty Vision Products Launches New 28 Lens Zenlens Dx Set 154
  • 6.58 Dec 12, 2016: Valeant Appoints William D. Humphries As EVP, Dermatology 154
  • 6.59 Dec 09, 2016: Carl Zeiss Meditec continues its growth trend 155
  • 6.60 Dec 08, 2016: The Cooper Companies Announces Fourth Quarter and Full Year 2016 Results 156
  • 6.61 Dec 07, 2016: Essilor Realigns its Organization with its Growing Businesses 157
  • 6.62 Dec 07, 2016: VTI names executive director of manufacturing and engineering 158
  • 6.63 Dec 07, 2016: Visioneering Technologies Announces Ms. Rosa Lee as New Executive Director of Manufacturing & Engineering 158
  • 6.64 Nov 29, 2016: Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda 159
  • 6.65 Nov 17, 2016: Former Valeant Executive And Former Philidor Ceo Charged In Manhattan Federal Court For Illegal Fraud And Kickback Scheme 160
  • 6.66 Nov 10, 2016: Alcon introduces new AIR OPTIX plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting 161
  • 6.67 Nov 09, 2016: New Study Shows Groundbreaking Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% Over Two Years 162
  • 6.68 Nov 09, 2016: Daniel B. Polley, Ph.D., appointed Director of Lauer Tinnitus Research Center at Mass. Eye and Ear 164
  • 6.69 Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 165
  • 6.70 Oct 28, 2016: Hoya Reports Second Quarter Results 168
  • 6.71 Oct 27, 2016: VTI Introduces the NaturalVue Multifocal QuickStart Calculator 169
  • 6.72 Oct 26, 2016: Edmund Optics and Varioptic Announce the Availability of the Variable Focus Arctic Liquid Lens in the EO Catalog 169
  • 6.73 Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters 170
  • 6.74 Oct 21, 2016: Essilor: Nine-Month Consolidated Revenue up 7.8% at Constant Exchange Rates 177
  • 6.75 Oct 13, 2016: Carl Zeiss Meditec appoints Steven C. Schallhorn, MD as Chief Medical Officer 179
  • 6.76 Oct 12, 2016: Bausch + Lomb Booth to Feature Wet Lab During the Annual Meeting of the American Academy of Ophthalmology in Chicago 180
  • 6.77 Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 182
  • 6.78 Sep 01, 2016: The Cooper Companies CFO Gregory W. Matz to Retire; Albert G. White Named Successor in Planned Transition 183
  • 6.79 Sep 01, 2016: The Cooper Companies Announces Third Quarter 2016 Results 184
  • 6.80 Aug 29, 2016: Drug-dispensing contact lens effectively lowers eye pressure in pre-clinical glaucoma model 184
  • 6.81 Aug 29, 2016: Drug Dispensing Contact lens Effectively Lowers Eye Pressure in Pre clinical Glaucoma Model 186
  • 6.82 Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 187
  • 6.83 Aug 15, 2016: CooperVision Unveils Avaira Vitality Sphere and Toric Two-Week Contact Lenses 188
  • 6.84 Aug 12, 2016: Carl Zeiss Meditec Grows in Ophthalmology and Microsurgery 189
  • 6.85 Aug 11, 2016: Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent Results 190
  • 6.86 Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 190
  • 6.87 Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 190
  • 6.88 Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 192
  • 6.89 Aug 01, 2016: Essilor International: Improving Lives by Improving Sight 194
  • 6.90 Jul 29, 2016: Essilor - First-Half 2016 Results: Revenue Up 8.1% Excluding the Currency Effect 195
  • 6.91 Jul 29, 2016: Hoya Reports First Quarter Financial Results 199
  • 6.92 Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 199
  • 6.93 Jul 27, 2016: Carl Zeiss Meditec Recruits James V. Mazzo to Lead Its Newly Consolidated Ophthalmology Organization 200

7 Appendix 201

  • 7.1 Methodology 201
  • 7.2 About GlobalData 204
  • 7.3 Contact Us 204
  • 7.4 Disclaimer 204

List of Tables

1.1 List of Tables

  • Table 1: Contact Lenses - Pipeline Products by Stage of Development 13
  • Table 2: Contact Lenses - Pipeline Products by Segment 14
  • Table 3: Contact Lenses - Pipeline Products by Territory 15
  • Table 4: Contact Lenses - Pipeline Products by Regulatory Path 16
  • Table 5: Contact Lenses - Pipeline Products by Estimated Approval Date 17
  • Table 6: Contact Lenses - Ongoing Clinical Trials 18
  • Table 7: Contact Lenses Companies - Pipeline Products by Stage of Development 19
  • Table 8: Contact Lenses - Pipeline Products by Stage of Development 21
  • Table 9: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 10: Biolens - Product Status 23
  • Table 11: Biolens - Product Description 23
  • Table 12: Contact Lens - Product Status 24
  • Table 13: Contact Lens - Product Description 24
  • Table 14: Alcon Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 15: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Status 25
  • Table 16: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Description 26
  • Table 17: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Status 26
  • Table 18: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Product Description 26
  • Table 19: Dailies Total 1 Colors SiHy Lens - Product Status 27
  • Table 20: Dailies Total 1 Colors SiHy Lens - Product Description 27
  • Table 21: Dailies Total 1 Toric SiHy Lens - Product Status 27
  • Table 22: Dailies Total 1 Toric SiHy Lens - Product Description 27
  • Table 23: Smart Contact Lens - Diabetes - Product Status 28
  • Table 24: Smart Contact Lens - Diabetes - Product Description 28
  • Table 25: Weekly WG SiHy Lens - Product Status 28
  • Table 26: Weekly WG SiHy Lens - Product Description 29
  • Table 27: Alcon Laboratories Inc - Ongoing Clinical Trials Overview 30
  • Table 28: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - Clinical Assessment of a Regimen of AIR OPTIX plus HYDRAGLYDE Silicone Hydrogel Lenses and HYDRAGLYDE Containing Lens Care Solutions 31
  • Table 29: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Overnight And Flexible Wear - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 31
  • Table 30: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors 32
  • Table 31: Apeliotus Ophthalmics (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 32: Comfort Lens - Product Status 33
  • Table 33: Comfort Lens - Product Description 33
  • Table 34: Contact Lens - Glaucoma - Product Status 34
  • Table 35: Contact Lens - Glaucoma - Product Description 34
  • Table 36: Auburn University Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 37: Smart Contact Lenses - Product Status 35
  • Table 38: Smart Contact Lenses - Product Description 35
  • Table 39: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 40: MC - PHEMA Based Contact Lens - Product Status 36
  • Table 41: MC - PHEMA Based Contact Lens - Product Description 36
  • Table 42: Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 43: Bionic Contact Lens - Product Status 37
  • Table 44: Bionic Contact Lens - Product Description 37
  • Table 45: Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 46: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Status 38
  • Table 47: Bausch + Lomb ULTRA Astigmatism Contact Lens - Product Description 39
  • Table 48: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Status 39
  • Table 49: Bausch + Lomb ULTRA Presbyopia Contact Lens - Product Description 40
  • Table 50: Ultra Plus Powers Lens - Product Status 40
  • Table 51: Ultra Plus Powers Lens - Product Description 41
  • Table 52: Ultra Toric Lens - Product Status 41
  • Table 53: Ultra Toric Lens - Product Description 41
  • Table 54: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 55: Contact Lens Drug Delivery Device - Product Status 42
  • Table 56: Contact Lens Drug Delivery Device - Product Description 42
  • Table 57: CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 58: Biofinity Energys - Product Status 43
  • Table 59: Biofinity Energys - Product Description 43
  • Table 60: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Status 44
  • Table 61: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Description 44
  • Table 62: SiH Multifocal - Product Status 44
  • Table 63: SiH Multifocal - Product Description 45
  • Table 64: CooperVision Inc - Ongoing Clinical Trials Overview 46
  • Table 65: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - A Multi-center Dispensing Clinical Evaluation of MiSight Lenses 47
  • Table 66: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Efficacy and Safety of MiSight Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial 47
  • Table 67: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 68: EP Global Contact Lens - Product Status 48
  • Table 69: EP Global Contact Lens - Product Description 48
  • Table 70: Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 71: Drug-Eluting Contact Lenses - Product Status 49
  • Table 72: Drug-Eluting Contact Lenses - Product Description 49
  • Table 73: e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 74: Electronic Contact Lens - Product Status 50
  • Table 75: Electronic Contact Lens - Product Description 50
  • Table 76: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 77: Drug Dispensing Contact Lens - Product Status 51
  • Table 78: Drug Dispensing Contact Lens - Product Description 51
  • Table 79: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 80: Hyper-CL - Drug Delivery - Product Status 52
  • Table 81: Hyper-CL - Drug Delivery - Product Description 52
  • Table 82: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 83: Contact Lens - Product Status 53
  • Table 84: Contact Lens - Product Description 53
  • Table 85: Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview 54
  • Table 86: 1-DAY ACUVUE Multifocal Contact Lens - Product Status 54
  • Table 87: 1-DAY ACUVUE Multifocal Contact Lens - Product Description 54
  • Table 88: Anti-allergic Contact Lens - Product Status 55
  • Table 89: Anti-allergic Contact Lens - Product Description 55
  • Table 90: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview 56
  • Table 91: Therapeutic Contact Lens - Product Status 56
  • Table 92: Therapeutic Contact Lens - Product Description 56
  • Table 93: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 94: CLM041 - Product Status 57
  • Table 95: CLM041 - Product Description 57
  • Table 96: Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 97: Contact Lens - Dry Eye Disease - Product Status 58
  • Table 98: Contact Lens - Dry Eye Disease - Product Description 58
  • Table 99: Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 100: Third PEG Hydrogel Contact Lens - Product Status 59
  • Table 101: Third PEG Hydrogel Contact Lens - Product Description 59
  • Table 102: Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 103: Presbia Flexivue Microlens - Product Status 60
  • Table 104: Presbia Flexivue Microlens - Product Description 60
  • Table 105: Presbia Plc - Ongoing Clinical Trials Overview 61
  • Table 106: Presbia Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes 62
  • Table 107: RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 108: CLEAr Lens - Product Status 63
  • Table 109: CLEAr Lens - Product Description 63
  • Table 110: Stanford University Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 111: Polymer Network Hydrogel Contact Lens - Product Status 64
  • Table 112: Polymer Network Hydrogel Contact Lens - Product Description 64
  • Table 113: SynergEyes Inc Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 114: Duette Progressive With Tangible Hydra-PEG - Product Status 65
  • Table 115: Duette Progressive With Tangible Hydra-PEG - Product Description 65
  • Table 116: Duette With Tangible Hydra-PEG - Product Status 66
  • Table 117: Duette With Tangible Hydra-PEG - Product Description 66
  • Table 118: The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 119: Resonance Circuit Sensor Contact Lens - Product Status 67
  • Table 120: Resonance Circuit Sensor Contact Lens - Product Description 67
  • Table 121: The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 122: Stem Cell Contact Lens - Product Status 68
  • Table 123: Stem Cell Contact Lens - Product Description 68
  • Table 124: UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 125: Contact Lenses - Product Status 69
  • Table 126: Contact Lenses - Product Description 69
  • Table 127: University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 128: Aerated Contact Lens - Product Status 70
  • Table 129: Aerated Contact Lens - Product Description 70
  • Table 130: Telescopic Contact Lens - Product Status 71
  • Table 131: Telescopic Contact Lens - Product Description 71
  • Table 132: University of Florida Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 133: Vitamin E - Packed Lenses - Product Status 72
  • Table 134: Vitamin E - Packed Lenses - Product Description 72
  • Table 135: University of Valencia Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 136: Multifocal Contact Lens - Myopia - Product Status 73
  • Table 137: Multifocal Contact Lens - Myopia - Product Description 73
  • Table 138: Multifocal Contact Lens - Presbyopia - Product Status 74
  • Table 139: Multifocal Contact Lens - Presbyopia - Product Description 74
  • Table 140: University of Washington Pipeline Products & Ongoing Clinical Trials Overview 75
  • Table 141: Bionic Contact Lens - Product Status 75
  • Table 142: Bionic Contact Lens - Product Description 75
  • Table 143: Solar Powered Augmented Lenses - Product Status 76
  • Table 144: Solar Powered Augmented Lenses - Product Description 76
  • Table 145: Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview 77
  • Table 146: Biotrue ONEday Toric Lenses - ASTIGMATISM - Product Status 78
  • Table 147: Biotrue ONEday Toric Lenses - ASTIGMATISM - Product Description 78
  • Table 148: BLC - 001: SVS - Product Status 78
  • Table 149: BLC - 001: SVS - Product Description 79
  • Table 150: BLC - 002: SVS - Product Status 79
  • Table 151: BLC - 002: SVS - Product Description 79
  • Table 152: BLC - 003: SVS/MF/fA - Product Status 80
  • Table 153: BLC - 003: SVS/MF/fA - Product Description 80
  • Table 154: BLC - 004: Toric - Product Status 80
  • Table 155: BLC - 004: Toric - Product Description 81
  • Table 156: BLC - 005: SVS/MF - Product Status 81
  • Table 157: BLC - 005: SVS/MF - Product Description 81
  • Table 158: BLC - 006: SVS - Product Status 82
  • Table 159: BLC - 006: SVS - Product Description 82
  • Table 160: BLC - 007: MF - Product Status 82
  • Table 161: BLC - 007: MF - Product Description 83
  • Table 162: BLC - 008: Astigmatism - Product Status 83
  • Table 163: BLC - 008: Astigmatism - Product Description 83
  • Table 164: BLC - 009: Astigmatism - Product Status 83
  • Table 165: BLC - 009: Astigmatism - Product Description 84
  • Table 166: XUV - 003: Aphakia - Product Status 84
  • Table 167: XUV - 003: Aphakia - Product Description 84
  • Table 168: XUV - 004: SVS - Product Status 84
  • Table 169: XUV - 004: SVS - Product Description 85
  • Table 170: XUV - 007: MF - Product Status 85
  • Table 171: XUV - 007: MF - Product Description 85
  • Table 172: XUV - 009: SVS - Product Status 86
  • Table 173: XUV - 009: SVS - Product Description 86
  • Table 174: XUV - 010: Astigmatism - Product Status 86
  • Table 175: XUV - 010: Astigmatism - Product Description 87
  • Table 176: XUV - 011: MF - Product Status 87
  • Table 177: XUV - 011: MF - Product Description 87
  • Table 178: XUV - 012: SVS - Product Status 87
  • Table 179: XUV - 012: SVS - Product Description 88
  • Table 180: XUV - 013: Astigmatism - Product Status 88
  • Table 181: XUV - 013: Astigmatism - Product Description 88
  • Table 182: XUV - 014: Presbyopia - Product Status 89
  • Table 183: XUV - 014: Presbyopia - Product Description 89
  • Table 184: XUV - 015: MF - Product Status 89
  • Table 185: XUV - 015: MF - Product Description 89
  • Table 186: Visioneering Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 90
  • Table 187: Contact Lens - Product Status 90
  • Table 188: Contact Lens - Product Description 90
  • Table 189: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses - Product Status 91
  • Table 190: NaturalVue (etafilcon A) Sphere 1 Day Contact Lenses - Product Description 91
  • Table 191: NaturalVue Toric 1 Day Contact Lenses - Product Status 91
  • Table 192: NaturalVue Toric 1 Day Contact Lenses - Product Description 92
  • Table 193: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Status 92
  • Table 194: NaturalVue Toric Multifocal 1 Day Contact Lenses - Product Description 92
  • Table 195: VTI MPC Lens - Product Status 93
  • Table 196: VTI MPC Lens - Product Description 93
  • Table 197: VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview 94
  • Table 198: K-Lens - Product Status 94
  • Table 199: K-Lens - Product Description 94
  • Table 200: Yolia Health Pipeline Products & Ongoing Clinical Trials Overview 95
  • Table 201: TVT Device - Product Status 95
  • Table 202: TVT Device - Product Description 95
  • Table 203: Glossary 203

List of Figures

1.2 List of Figures

  • Figure 1: Contact Lenses - Pipeline Products by Stage of Development 13
  • Figure 2: Contact Lenses - Pipeline Products by Segment 14
  • Figure 3: Contact Lenses - Pipeline Products by Territory 15
  • Figure 4: Contact Lenses - Pipeline Products by Regulatory Path 16
  • Figure 5: Contact Lenses - Pipeline Products by Estimated Approval Date 17
  • Figure 6: Contact Lenses - Ongoing Clinical Trials 18
Back to Top